BioCentury
ARTICLE | Emerging Company Profile

Zelluna’s solid TCR plans

Why Zelluna plans to enter solid tumor territory with patient-sourced TCRs

January 17, 2019 1:07 PM UTC

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development.

CEO Miguel Forte said Zelluna’s products are built on a large portfolio of TCRs against antigens that are critical to tumor survival: TERT, KRAS and TGFBR2. Oslo University Hospital obtained the portfolio by isolating and sequencing TCRs from the blood samples from a small number of solid tumor patients who had survived as long as 10 years after immunization with TERT, KRAS or TGFBR2 peptides...